Conversely, malignant insulinomas often do express the somatostatin receptor subtype 2 (SST2), which can be targeted using PET/CT using 68Ga-DOTA-labeled somatostatin analogs (SSAs), or with somatostatin receptor scintigraphy and SPECT. The gene discussed is SSTR2; the disease is pancreatic insulinoma.